The clinical potential of gene editing as a tool to engineer cell‐based therapeutics

The clinical application of ex vivo gene edited cell therapies first began a decade ago with zinc finger nuclease editing of autologous CD4 + T‐cells. Editing aimed to disrupt expression of the human immunodeficiency virus co‐receptor gene CCR5 , with the goal of yielding cells resistant to viral entry, prior to re‐infusion into the patient. Since then the field has substantially evolved with the arrival of the new editing technologies...